Home » Stocks » 89bio

89bio, Inc. (ETNB)

Stock Price: $27.60 USD -0.57 (-2.02%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 380.71M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 13.79M
EPS (ttm) -72.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $27.60
Previous Close $28.17
Change ($) -0.57
Change (%) -2.02%
Day's Open 26.30
Day's Range 26.00 - 29.76
Day's Volume 80,777
52-Week Range 14.00 - 47.25

More Stats

Market Cap 380.71M
Enterprise Value 295.16M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.79M
Float 1.97M
EPS (basic) n/a
EPS (diluted) -72.33
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 566,902
Short Ratio 14.78
Short % of Float 14.18%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.33
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 85.56M
Net Cash / Share 6.20
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -31.14%
ROE -116.43%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(60.33% upside)
Current: 27.60
Target: 44.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.64-15.16
Net Income-57.42-16.18
Shares Outstanding2.340.44
Earnings Per Share-24.49-36.45
Operating Cash Flow-25.46-12.47
Capital Expenditures-0.14-0.04
Free Cash Flow-25.60-12.51
Cash & Equivalents93.3611.26
Net Cash / Debt93.3611.26
Book Value89.94-16.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name 89bio, Inc.
Country United States
Employees 22
CEO Rohan Palekar

Stock Information

Ticker Symbol ETNB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ETNB


89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is BIO89-100, an engineered glycoPEGylated analog of fibroblast growth factor 21 that is in proof of concept Phase 1b/2a clinical trial in patients with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver diseases with a high risk of NASH. It also focuses on the development and commercialization of other therapies related to NASH, and other liver and cardio-metabolic diseases. The company was founded in 2018 and is headquartered in San Francisco, California.